William Rice - Aptose Biosciences Chairman, CEO and Pres
| APTODelisted Stock | USD 2.01 0.91 82.73% |
Chairman
Dr. William G. Rice, Ph.D., was appointed as Chairman of the Board, President, Chief Executive Officer of Aptose Biosciences Inc., with effect from October 28, 2013. Prior to joining Lorus, Dr. Rice served as the President, Chief Executive Officer and Chairman of the board of Cylene Pharmaceuticals, Inc., a private biotechnology company . Prior to Cylene, Dr. Rice was the founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute Frederick Cancer Research and Development Center, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine since 2013.
| Age | 66 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Phone | 647 479 9828 |
| Web | https://www.aptose.com |
William Rice Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Rice against Aptose Biosciences stock is an integral part of due diligence when investing in Aptose Biosciences. William Rice insider activity provides valuable insight into whether Aptose Biosciences is net buyers or sellers over its current business cycle. Note, Aptose Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aptose Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Rice over a year ago Acquisition by William Rice of 70000 shares of Aptose Biosciences subject to Rule 16b-3 |
Aptose Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.4226) % which means that it has lost $1.4226 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9413) %, meaning that it created substantial loss on money invested by shareholders. Aptose Biosciences' management efficiency ratios could be used to measure how well Aptose Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Aptose Biosciences currently holds 621 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Aptose Biosciences has a current ratio of 6.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aptose Biosciences' use of debt, we should always consider it together with its cash and equity.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Aptose Bioscns operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Aptose Biosciences (APTO) is traded on NASDAQ Exchange in USA and employs 35 people. Management Performance
| Return On Equity | -6.94 | |||
| Return On Asset | -1.42 |
Aptose Biosciences Leadership Team
Elected by the shareholders, the Aptose Biosciences' board of directors comprises two types of representatives: Aptose Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptose. The board's role is to monitor Aptose Biosciences' management team and ensure that shareholders' interests are well served. Aptose Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptose Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philippe Ledru, Senior Officer | ||
| Fletcher Payne, CFO, VP | ||
| Janet CA, VP Fin | ||
| Rafael MD, Senior Officer | ||
| Roger BSc, Vice Operations | ||
| Marc Wiles, Senior Affairs | ||
| Brooks MBA, VP Controller | ||
| William Rice, Chairman, CEO and Pres |
Aptose Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aptose Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.94 | |||
| Return On Asset | -1.42 | |||
| Current Valuation | 9.69 M | |||
| Shares Outstanding | 2.55 M | |||
| Shares Owned By Insiders | 24.80 % | |||
| Shares Owned By Institutions | 11.51 % | |||
| Number Of Shares Shorted | 53.15 K | |||
| Price To Earning | (1.80) X | |||
| Price To Book | 67.84 X | |||
| EBITDA | (36.15 M) |
Pair Trading with Aptose Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Aptose Stock
Moving against Aptose Stock
| 0.89 | USPH | US Physicalrapy | PairCorr |
| 0.85 | CGECF | Cogeco Inc | PairCorr |
| 0.84 | EMMA | Emmaus Life Sciences | PairCorr |
| 0.83 | GS | Goldman Sachs Group | PairCorr |
| 0.82 | GRBK | Green Brick Partners | PairCorr |
The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.
The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Aptose Stock
If you are still planning to invest in Aptose Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aptose Biosciences' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities |